Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial.

MLA

Cibula, David, et al. “Dendritic Cell-Based Immunotherapy (DCVAC/OvCa) Combined with Second-Line Chemotherapy in Platinum-Sensitive Ovarian Cancer (SOV02): A Randomized, Open-Label, Phase 2 Trial.” Gynecologic Oncology, vol. 162, no. 3, Sept. 2021, pp. 652–60. EBSCOhost, https://doi.org/10.1016/j.ygyno.2021.07.003.

APA

Cibula, D., Rob, L., Mallmann, P., Knapp, P., Klat, J., Chovanec, J., Minar, L., Melichar, B., Hein, A., Kieszko, D., Pluta, M., Spacek, J., Bartos, P., Wimberger, P., Madry, R., Markowska, J., Streb, J., Valha, P., Hassan, H. I. B., … Spisek, R. (2021). Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial. Gynecologic Oncology, 162(3), 652–660. https://doi.org/10.1016/j.ygyno.2021.07.003

Chicago

Cibula, David, Lukas Rob, Peter Mallmann, Pawel Knapp, Jaroslav Klat, Josef Chovanec, Lubos Minar, et al. 2021. “Dendritic Cell-Based Immunotherapy (DCVAC/OvCa) Combined with Second-Line Chemotherapy in Platinum-Sensitive Ovarian Cancer (SOV02): A Randomized, Open-Label, Phase 2 Trial.” Gynecologic Oncology 162 (3): 652–60. doi:10.1016/j.ygyno.2021.07.003.